Hillstream BioPharma

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

Our mission is to revolutionize the way people access and use our products, fostering collaboration and innovation in order to develop treatments that will improve the quality of life for people around the world.

We are committed to providing innovative and transformative therapies to improve patient care and outcomes. We strive to be a leader in the biotechnology industry, leveraging our expertise and knowledge to create impactful therapies that benefit people everywhere.

Hillstream Biopharma has received numerous awards for its innovative products and dedication to providing top-notch care for its patients. These awards include the Pharma Award for Innovation in Therapeutics, the Pharma Times Biotechnology Excellence Award and the World Health Organization’s Awards for Excellence in Healthcare Innovation.